文献速递骨质疏松与代谢性骨病

抗癫痫药物治疗与骨丢失:一项双生子与同胞研究

Bone loss with antiepileptic drug therapy: a twin and sibling study.
PubMed 文献 · Osteoporos Int · 2017-06-06

在48对同性双生子/年龄匹配同胞(用药不一致)中评估抗癫痫药物(AED)使用与骨丢失的关系。AED使用者在髋部各区域骨密度降低;长期使用及酶诱导型AED使用者骨密度丢失更大,预测骨脆性风险更高。作者指出需进一步前瞻性研究AED对骨微结构的影响。

要点

  • AED使用者在全髋、股骨颈和转子区骨密度较非使用者降低(P<0.05)。
  • 酶诱导型AED使用者全髋和全身骨密度年丢失率大于非使用者(P=0.013和P=0.019)。
  • AED使用超过20年预测前臂、全身骨密度及全身骨矿含量更高丢失(P=0.028、P=0.010、P=0.031)。

核心结论

  • AED使用者髋部区域面积骨密度降低,长期使用者和酶诱导型AED使用者骨密度丢失更大,预测骨脆性风险更高。
  • 作者指出需进一步前瞻性研究AED对骨微结构的影响。

研究设计与样本

  • 研究纳入48对同性双生子或年龄匹配同胞(40对女性,8对男性),每对中一人使用AED、另一人不使用。
  • 采用双能X射线吸收测定法(DXA)至少间隔2年两次测量髋部区域、前臂、腰椎和全身的面积骨密度(aBMD)和骨矿含量(BMC)。
  • 计算组内平均差异(MWPD)、MWPD%和aBMD年变化率,并校正年龄、体重和身高。

主要发现

  • 基线和随访时,AED使用者较非使用者全髋aBMD的MWPD%分别为3.8%和4.4%,股骨颈为4.7%和4.5%,转子区为4.1%和4.6%(P<0.05)。
  • 全队列中,所有aBMD/BMC区域的年变化率在组内无显著差异(P>0.05)。
  • 酶诱导型AED使用者(20对)较非使用者全髋aBMD年丢失率1.7% vs 0.3%(P=0.013),全身区域为年丢失0.7% vs 年增加0.1%(P=0.019);非酶诱导型AED不一致对(16对)中未发现此差异。
  • AED使用超过20年预测前臂aBMD(P=0.028)、全身aBMD(P=0.010)和全身BMC(P=0.031)更高丢失。

局限性

  • 作者指出需进一步前瞻性研究AED对骨微结构的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Changes in areal bone mineral density (aBMD) and other predictors of bone loss were evaluated in 48 same-sex twin/age-matched sibling pairs discordant for antiepileptic drug (AED) use. AED users had reduced BMD at the hip regions. Prolonged AED users had greater aBMD loss, predicting a higher risk of bone fragility. INTRODUCTION: To investigate the longitudinal associations of bone mineral measures with antiepileptic drug (AED) use, including enzyme-inducing (EIAED) and non-enzyme-inducing (NEIAED) types, and other predictors of bone loss in a study of 48 same-sex twin/age-matched sibling pairs (40 female, 8 male) discordant for AED use. METHODS: Using dual-energy X-ray absorptiometry (DXA), areal bone mineral density (aBMD) and content (BMC) at the hip regions, forearm, lumbar spine, and whole body were measured twice, at least 2 years apart. The mean within-pair difference (MWPD), MWPD%, and mean annual rate of aBMD change were adjusted for age, weight, and height. Predictors of bone loss were evaluated. RESULTS: AED users, compared to non-users, at baseline and follow-up, respectively, had reduced aBMD at the total hip (MWPD% 3.8, 4.4%), femoral neck (4.7, 4.5%), and trochanter regions (4.1, 4.6%) (p < 0.05). For the whole cohort, the annual rate of change in all aBMD/BMC (p > 0.05) regions did not differ within pairs. Nevertheless, EIAED users had greater aBMD loss than non-users (n = 20 pairs) at the total hip (1.7 vs. 0.3%, p = 0.013) and whole body regions (0.7% loss vs. 0.1% BMD gain, p = 0.019), which was not found in NEIAED-discordant pairs (n = 16). AED use >20 years predicted higher aBMD loss at the forearm (p = 0.028), whole body (p = 0.010), and whole body BMC (p = 0.031). CONCLUSIONS: AED users had reduced aBMD at the hip regions. Prolonged users and EIAED users had greater aBMD loss, predicting a higher risk of bone fragility. Further prospective studies of AED effects on bone microarchitecture are needed.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Shiek Ahmad B, Petty SJ, Gorelik A, et al. Bone loss with antiepileptic drug therapy: a twin and sibling study. Osteoporos Int. 2017. PMID: 28589417. doi:10.1007/s00198-017-4098-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。